Explores Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases (CPM). Success relies entirely on meticulous patient selection and achieving complete macroscopic cytoreduction (CC0). The episode details the Peritoneal Cancer Index (PCI) for staging and emphasizes that for aggressive CPM, CC1 is essentially a failure to cure, whereas it may be acceptable for less aggressive PMP. The landmark Verwall trial proved a survival benefit for CRS + Mitomycin C HIPEC. However, the PRODIGE 7 trial introduced controversy by showing no survival benefit when using Oxaliplatin HIPEC after successful CRS alone, suggesting the choice of agent is critical. Current practice is shifting toward prevention and early detection in high-risk patients (e.g., T4 tumors, perforation).